Unisanté Revenue and Competitors
Estimated Revenue & Valuation
- Unisanté's estimated annual revenue is currently $199.1M per year.
- Unisanté's estimated revenue per employee is $337,500
Employee Data
- Unisanté has 590 Employees.
- Unisanté grew their employee count by 5% last year.
Unisanté's People
Name | Title | Email/Phone |
---|---|---|
1 | Research Fellow | Reveal Email/Phone |
Unisanté Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $214.3M | 635 | 1% | N/A | N/A |
#2 | $199.1M | 590 | 5% | N/A | N/A |
#3 | $49.9M | 168 | 37% | N/A | N/A |
#4 | $20.5M | 76 | 7% | N/A | N/A |
#5 | $27.8M | 103 | 6% | N/A | N/A |
#6 | $104M | 308 | 7% | N/A | N/A |
#7 | $49.3M | 166 | 7% | N/A | N/A |
#8 | $403.3M | 1067 | 11% | N/A | N/A |
#9 | $44M | 148 | 20% | N/A | N/A |
#10 | $4.7M | 25 | 9% | N/A | N/A |
What Is Unisanté?
Depuis le 1er janvier 2019, la Policlinique médicale universitaire, l'Institut universitaire de médecine sociale et préventive, l'Institut universitaire romand de santé au travail et l'association Promotion Santé Vaud, forment Unisanté, Centre universitaire de médecine générale et santé publique à Lausanne.
keywords:N/AN/A
Total Funding
590
Number of Employees
$199.1M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Unisanté News
2022-04-17 - Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue
Fever and Coronavirus T cell Adaptive Vaccines
Phase I clinical trial at a single site in Switzerland (Unisanté, Lausanne) with 52 participants. The two stages of the trial are designed...
2022-03-22 - Moselle. Conservatoire de Forbach : une convention signée avec le CHIC
Unisanté et lAgglo
Moselle Conservatoire de Forbach : une convention signée avec le CHIC Unisanté et l'Agglo. Ce jeudi matin, les représentants du centre...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $98.8M | 608 | 5% | N/A |
#2 | $630.9M | 2146 | 3% | N/A |
#3 | $1383.3M | 4066 | 5% | N/A |
#4 | $1471.5M | 7321 | 5% | N/A |
#5 | $5008.2M | 15690 | 12% | N/A |